PDE4A and chronic obstructive pulmonary disease: Mechanistically these findings indicate that despite the concomitant use of ICS, COPD patients with higher eosinophilic counts display a specific profile of type-2 and PDE4 related airway inflammation that may be targeted with PDE4 inhibitors.